Patent classifications
C07K14/36
Expression of recombinant tetracycline efflux pumps for the production of lysine or lysine-derived products, and methods and applications thereof
One aspect of the invention relates to a mutant polypeptide comprising the amino acid sequence of Escherichia coli tetracycline efflux pump A (TetA). Another aspect of the invention relates to a polynucleotide encoding a polypeptide of TetA, a fragment thereof, or a mutant thereof. Another aspect of the invention relates to a first expression plasmid vector comprising one or more first polynucleotides encoding a first polypeptide comprising a tetracycline efflux pump polypeptide, a fragment thereof or a mutant thereof, one or more second polynucleotides independently selected from the group consisting of a third polynucleotide encoding a third polypeptide comprising a lysine decarboxylase polypeptide, a fragment thereof or a mutant thereof, and a fourth polynucleotide encoding a fourth polypeptide comprising a lysine biosynthesis polypeptide, a fragment thereof or a mutant thereof. Another aspect of the invention relates to a transformant comprising one or more expression plasmid vectors as described herein in a host cell. Another aspect of the invention relates to a mutant host cell comprising one or more first, third or fourth polynucleotides as described herein integrated into a chromosome of a host cell. Another aspect of the invention relates to a method for producing a lysine comprising obtaining a transformant and/or mutant host cell as disclosed herein, culturing the transformant and/or mutant host cell under conditions effective for the expression of the lysine; and harvesting the lysine. Other aspects of the invention relate to methods for producing biobased cadaverine using the transformants disclosed herein, and biobased cadaverine prepared by the method disclosed herein, and polyamides formed using the biobased cadaverine as disclosed herein and compositions thereof.
COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.
COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.
METHODS AND MATERIALS FOR TREATING CANCER
This document provides methods and materials involved in treating cancer. For example, compositions containing a fusion polypeptide (or a polypeptide conjugate) having a tumor-targeting moiety and a phagocyte engaging moiety as well as methods and materials for using such compositions to treat cancer are provided.
METHODS AND MATERIALS FOR TREATING CANCER
This document provides methods and materials involved in treating cancer. For example, compositions containing a fusion polypeptide (or a polypeptide conjugate) having a tumor-targeting moiety and a phagocyte engaging moiety as well as methods and materials for using such compositions to treat cancer are provided.
Compositions, methods and therapies for administering antigen peptide
The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.
Compositions, methods and therapies for administering antigen peptide
The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.
STREPTAVIDIN MUTEINS AND METHODS OF USING THEM
The invention concerns novel streptavidin muteins. In one embodiment such a the mutein (a) contains at least two cysteine residues in the region of the amino acid positions 44 to 53 with reference to the amino acid sequence of wild type streptavidin as set forth at SEQ ID NO: 212 and (b) has a higher binding affinity than (i) a streptavidin mutein “1” (SEQ ID NO: 112) that comprises the amino acid sequence Val.sup.44-Thr.sup.45-Ala.sup.46-Arg.sup.47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
STREPTAVIDIN MUTEINS AND METHODS OF USING THEM
The invention concerns novel streptavidin muteins. In one embodiment such a the mutein (a) contains at least two cysteine residues in the region of the amino acid positions 44 to 53 with reference to the amino acid sequence of wild type streptavidin as set forth at SEQ ID NO: 212 and (b) has a higher binding affinity than (i) a streptavidin mutein “1” (SEQ ID NO: 112) that comprises the amino acid sequence Val.sup.44-Thr.sup.45-Ala.sup.46-Arg.sup.47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
Fluorescent polymerase enzyme substrates having protein shields
Compositions, methods, and systems are provided for fluorescent polymerase enzyme substrates comprising protein shields for improving enzyme photostability in single molecule real time sequencing. Fluorescent polymerase enzyme substrates of the invention have a protein shield between the fluorescent dye moieties and nucleotide moieties of the polymerase enzyme substrate. The polymerase enzyme substrates have a nucleotide component and a dye component, each attached to a protein. The attachments can be covalent. The protein can, for example, prevent the direct interaction of the fluorescent dye moiety with the enzyme when carrying out nucleotide synthesis, preventing photodamage to the enzyme. The polymerase enzyme substrates of the invention can have multiple dyes and multiple nucleotide moieties.